Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

130 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Anti-Anisakis antibodies in colon cancer patients and their relationship with γδ T-cells.
Andreu-Ballester JC, Cuéllar C, Colmena-Zaragoza J, Galindo-Regal L, Hurtado-Marcos C, González-Fernández J, Balciscueta Z, García-Ballesteros C, López-Chuliá F, Jiménez AI, Llombart-Cussac A. Andreu-Ballester JC, et al. Among authors: llombart cussac a. Parasitol Res. 2024 Apr 25;123(4):196. doi: 10.1007/s00436-024-08216-y. Parasitol Res. 2024. PMID: 38662084 Free PMC article.
Latent Microsporidia Infection Prevalence as a Risk Factor in Colon Cancer Patients.
Redondo F, Hurtado-Marcos C, Izquierdo F, Cuéllar C, Fenoy S, Sáez Y, Magnet Á, Galindo-Regal L, Uribe N, López-Bañeres M, Jiménez AI, Llombart-Cussac A, Del Águila C, Andreu-Ballester JC. Redondo F, et al. Cancers (Basel). 2022 Oct 29;14(21):5342. doi: 10.3390/cancers14215342. Cancers (Basel). 2022. PMID: 36358760 Free PMC article.
Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3.
Goetz MP, Toi M, Huober J, Sohn J, Trédan O, Park IH, Campone M, Chen SC, Manso LM, Paluch-Shimon S, Freedman OC, O'Shaughnessy J, Pivot X, Tolaney SM, Hurvitz S, Llombart-Cussac A, André V, Saha A, van Hal G, Shahir A, Iwata H, Johnston SRD. Goetz MP, et al. Among authors: llombart cussac a. Ann Oncol. 2024 May 8:S0923-7534(24)00139-X. doi: 10.1016/j.annonc.2024.04.013. Online ahead of print. Ann Oncol. 2024. PMID: 38729566 Free article.
Preventing alpelisib-related hyperglycaemia in HR+/HER2-/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial.
Llombart-Cussac A, Pérez-Garcia JM, Ruiz Borrego M, Tolosa P, Blanch S, Fernández-Ortega A, Urruticoechea A, Blancas I, Saura C, Rojas B, Bermejo B, Ponce Lorenzo J, Gion M, Cortez-Castedo P, Llabres E, Galve E, Cueva JF, López A, Alonso-Romero JL, González-Santiago S, Martínez de Dueñas E, Ciruelos E, Martrat G, Gener P, Alcalá-López D, Sampayo-Cordero M, Gómez-Peralta F, Cortés J. Llombart-Cussac A, et al. EClinicalMedicine. 2024 Apr 11;71:102520. doi: 10.1016/j.eclinm.2024.102520. eCollection 2024 May. EClinicalMedicine. 2024. PMID: 38638399 Free PMC article.
Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial.
Llombart-Cussac A, Prat A, Pérez-García JM, Mateos J, Pascual T, Escrivà-de-Romani S, Stradella A, Ruiz-Borrego M, de Las Heras BB, Keyaerts M, Galvan P, Brasó-Maristany F, García-Mosquera JJ, Guiot T, Gion M, Sampayo-Cordero M, Di Cosimo S, Pérez-Escuredo J, de Frutos MA, Cortés J, Gebhart G. Llombart-Cussac A, et al. Eur J Nucl Med Mol Imaging. 2024 Apr 8. doi: 10.1007/s00259-024-06683-0. Online ahead of print. Eur J Nucl Med Mol Imaging. 2024. PMID: 38587643
3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.
Pérez-García JM, Cortés J, Ruiz-Borrego M, Colleoni M, Stradella A, Bermejo B, Dalenc F, Escrivá-de-Romaní S, Calvo Martínez L, Ribelles N, Marmé F, Cortés A, Albacar C, Gebhart G, Prat A, Kerrou K, Schmid P, Braga S, Di Cosimo S, Gion M, Antonarelli G, Popa C, Szostak E, Alcalá-López D, Gener P, Rodríguez-Morató J, Mina L, Sampayo-Cordero M, Llombart-Cussac A; PHERGain Trial Investigators. Pérez-García JM, et al. Among authors: llombart cussac a. Lancet. 2024 Apr 27;403(10437):1649-1659. doi: 10.1016/S0140-6736(24)00054-0. Epub 2024 Apr 3. Lancet. 2024. PMID: 38582092 Clinical Trial.
Optimal [18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial.
Gebhart G, Keyaerts M, Guiot T, Flamen P, Ruiz-Borrego M, Stradella A, Bermejo B, Escriva-de-Romani S, Calvo Martínez L, Ribelles N, Fernandez-Abad M, Albacar C, Colleoni M, Garrigos L, Atienza de Frutos M, Dalenc F, Prat A, Marmé F, Schmid P, Kerrou K, Braga S, Gener P, Sampayo-Cordero M, Cortés J, Pérez-García JM, Llombart-Cussac A. Gebhart G, et al. Among authors: llombart cussac a. J Nucl Med. 2024 May 1;65(5):708-713. doi: 10.2967/jnumed.123.266384. J Nucl Med. 2024. PMID: 38575192
Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab.
Gion M, García-Mosquera JJ, Pérez-García JM, Peg V, Ruiz-Borrego M, Stradella A, Bermejo B, Guerrero JA, López-Montero L, Mancino M, Rodríguez-Morató J, Antonarelli G, Sampayo-Cordero M, Llombart-Cussac A, Cortés J. Gion M, et al. Among authors: llombart cussac a. Breast Cancer Res Treat. 2024 Jun;205(3):589-598. doi: 10.1007/s10549-024-07292-z. Epub 2024 Mar 8. Breast Cancer Res Treat. 2024. PMID: 38456970
130 results